leadf
logo-loader
RNS
viewIntegumen

Integumen PLC - Labskin launches remote clinical skin trials

RNS Number : 9976T
Integumen PLC
24 July 2020
 

AIM share code: SKIN

24 July 2020

 

Integumen PLC

 

("Integumen" or "Company")

 

Labskin launches remote clinical skin trials

 

Virtual skin platform for disease diagnostics to offer individual skincare testing

 

Labskin, a subsidiary of Integumen, is pleased to announce the launch of the world's first remote clincal skin trials platform. By harvesting the microbiome of a human volunteer's skin, transporting it to the Labskin laboratory to be transplanted onto laboratory-grown skin, it creates an exact replica of the human volunteer's skin microflora - without them leaving their home.

Rinocloud software and AI division, another Integumen subsidiary, built a remote clinical skin trial platform; one that allows trials to happen ethically, efficiently with all protocols being followed and distantly controlled; where all data collected is stored according to the strictest of GDPR guidelines; and critically swabbing can be done under supervision in the human volunteer's own home - so no in-person contact is needed.

Labskin and Rinocloud together created the platform as an extensión to the Labskin AI virtual disease modeling development program that has already transformed the Integumen business model over the last 24 months. The platform is anchored in Labskin technology's ability to harvest and replicate a human subject's microbiome.

 

Gerard Brandon CEO Integumen plc  commented:

"With the spread of COVID-19 continuing to accelerate globally, the science and AI teams advanced this development over the last 3 monhts to create a virtual Clinical Research platform that has been disrupted by the lockdown. This has increased access to immune-suppressed, aged or infirm human volunteers without placing them at risk. It is being further adapted to undertake skin trials for individual consumers for cosmetic, skin disease diagnostics."

 

I look forward to updating the market very soon on progress with Integumen and other COVID-19 related programmes"

 

https://www.labskin.co.uk/remote-clinical-skin-trials/

 

Integumen plc

Gerard Brandon, CEO

 

+44 (0) 7340 055 648

SPARK Advisory Partners Limited

(Nominated Adviser)

 

Neil Baldwin/Andrew Emmott

+44 (0) 1203 368 3550

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker/Zoe Alexander

+44 (0) 20 3657 0050

 

About Integumen plc

Integumen is a scientific research and AI-as-a-Service company focused on production and analysis of bacteria, virus and toxins utilising artificial intelligent data analytics in regulatory technology, from scientifically proving the impact of skincare product claims on skin microbiome for top 10 global cosmetic company clients to remotely detecting water contamination in real-time.

 

About RNS Reach announcements

RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAFZGZNKDKGGZG

Quick facts: Integumen

Price: 49.5

Market: AIM
Market Cap: £56.03 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Market report: FTSE lacks direction and Japan's PM resigns

An up and down start for the FTSE 100 today following the news Japan's longest-serving Prime Minister has resigned due to health issues. Other main headlines today - Walmart (NYSE:WMT) has confirmed it's joining forces with Microsoft in a bid for the US assets of TikTok. It comes just...

3 weeks, 5 days ago